David A. Cooper

731 total citations
11 papers, 491 citations indexed

About

David A. Cooper is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, David A. Cooper has authored 11 papers receiving a total of 491 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 7 papers in Virology and 4 papers in Epidemiology. Recurrent topics in David A. Cooper's work include HIV Research and Treatment (7 papers), HIV/AIDS Research and Interventions (5 papers) and HIV/AIDS drug development and treatment (4 papers). David A. Cooper is often cited by papers focused on HIV Research and Treatment (7 papers), HIV/AIDS Research and Interventions (5 papers) and HIV/AIDS drug development and treatment (4 papers). David A. Cooper collaborates with scholars based in Australia, United Kingdom and United States. David A. Cooper's co-authors include Andrew Carr, Ronald Penny, John Kaldor, James W. Wells, B. Tindall, Louis Evans, Philip Cunningham, Anthony L. Cunningham, Jennifer C. Learmont and Gregory J. Dore and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Clinical Infectious Diseases.

In The Last Decade

David A. Cooper

11 papers receiving 476 citations

Peers

David A. Cooper

VIROL

EPIDE

IMMUN

Jane Yeo United Kingdom

Steve Felstead United Kingdom

A. Pozniak United Kingdom

Burke Ds United States

Sabine Kinloch‐de Loes United Kingdom

Zaïna Ait-Arkoub France

Beatriz Hernández‐Novoa Spain

Jane R Deayton United Kingdom

Lars Moberg Sweden

Paul D. Griffiths United Kingdom

Jane Yeo United Kingdom

David A. Cooper

350 ×1.0

VIROL

493 ×1.5

330 ×2.2

EPIDE

177 ×1.8

35 ×0.5

IMMUN

Citations per year, relative to David A. Cooper David A. Cooper (= 1×) peers Jane Yeo

Countries citing papers authored by David A. Cooper

Since Specialization

Citations

This map shows the geographic impact of David A. Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Cooper more than expected).

Fields of papers citing papers by David A. Cooper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Cooper. The network helps show where David A. Cooper may publish in the future.

Co-authorship network of co-authors of David A. Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Cooper. A scholar is included among the top collaborators of David A. Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Cooper. David A. Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Calmy, Alexandra, Kathy Petoumenos, Charlotte Lewden, et al.. (2007). Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts. HIV Medicine. 8(3). 171–180. 12 indexed citations

Autar, Reshma, Jintanat Ananworanich, Andrew Hill, et al.. (2004). Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. Journal of Antimicrobial Chemotherapy. 54(4). 785–790. 35 indexed citations

Dore, Gregory J. & David A. Cooper. (2001). The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses. Current Opinion in Infectious Diseases. 14(6). 749–755. 21 indexed citations

Boucher, Charles A., Françoise Brun‐Vézinet, Véronique Joly, et al.. (1999). Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial. International Journal of Antimicrobial Agents. 11(1). 13–21. 8 indexed citations

Benson, Elizabeth M., JACQUELINE A CLARKSON, Matthew Law, et al.. (1999). Therapeutic Vaccination with p24-VLP and Zidovudine Augments HIV-Specific Cytotoxic T Lymphocyte Activity in Asymptomatic HIV-Infected Individuals. AIDS Research and Human Retroviruses. 15(2). 105–113. 24 indexed citations

Vanhems, Philippe, Jean Lambert, David A. Cooper, et al.. (1998). Severity and Prognosis of Acute Human Immunodeficiency Virus Type 1 Illness: A Dose‐Response Relationship. Clinical Infectious Diseases. 26(2). 323–329. 61 indexed citations

Carr, Andrew & David A. Cooper. (1998). Lipodystrophy Associated with an HIV-Protease Inhibitor. New England Journal of Medicine. 339(18). 1296–1296. 77 indexed citations

Dore, Greg A., John Kaldor, Jennifer Hoy, et al.. (1996). Trends in AIDS-related illness in Australia: The Australian AIDS cohort. Murdoch Research Repository (Murdoch University). 2 indexed citations

Learmont, Jennifer C., B. Tindall, John Kaldor, et al.. (1992). Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. The Lancet. 340(8824). 863–867. 183 indexed citations

10.

Tenant‐Flowers, M, Michael J. Boyle, Dianne Carey, et al.. (1991). Sulphadiazine desensitization in patients with AIDS and cerebral toxoplasmosis. AIDS. 5(3). 311–316. 38 indexed citations

11.

Sculley, T B, Simone Cross, Persephone Borrow, & David A. Cooper. (1988). Prevalence of Antibodies to Epstein-Barr Virus Nuclear Antigen 2B in Persons Infected with the Human Immunodeficiency Virus. The Journal of Infectious Diseases. 158(1). 186–192. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact